Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q1 EPS of ($0.64), $0.01 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $2.59 million versus the consensus estimate of $3.94 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.